Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study

NCT04716933 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

201

Enrollment

INDUSTRY

Sponsor class

Conditions

Nonsquamous Non-small Cell Lung Cancer

Interventions

BIOLOGICAL: Pembrolizumab
DRUG: Carboplatin
DRUG: Cisplatin
DRUG: Pemetrexed
DRUG: Lenvatinib
DRUG: Placebo matching lenvatinib

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]